Kruczynski A - Search Results

1

Novel aspects of natural and modified vinca alkaloids.

Duflos A, Kruczynski A, Barret JM. Duflos A, et al. Among authors: kruczynski a. Curr Med Chem Anticancer Agents. 2002 Jan;2(1):55-70. doi: 10.2174/1568011023354452. Curr Med Chem Anticancer Agents. 2002. PMID: 12678751 Review.

2

Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.

Barret JM, Kruczynski A, Etiévant C, Hill BT. Barret JM, et al. Among authors: kruczynski a. Cancer Chemother Pharmacol. 2002 Jun;49(6):479-86. doi: 10.1007/s00280-002-0451-5. Epub 2002 Apr 6. Cancer Chemother Pharmacol. 2002. PMID: 12107553

3

Antitumor pharmacology -- quo vadis?

Bailly C, Barret JM, Kruczynski A. Bailly C, et al. Among authors: kruczynski a. Curr Med Chem Anticancer Agents. 2004 Sep;4(5):389-91. doi: 10.2174/1568011043352849. Curr Med Chem Anticancer Agents. 2004. PMID: 15379689 Review.

4

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT. Kruczynski A, et al. Biochem Pharmacol. 1998 Mar 1;55(5):635-48. doi: 10.1016/s0006-2952(97)00505-4. Biochem Pharmacol. 1998. PMID: 9515574

5

Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.

Etievant C, Barret JM, Kruczynski A, Perrin D, Hill BT. Etievant C, et al. Among authors: kruczynski a. Invest New Drugs. 1998;16(1):3-17. doi: 10.1023/a:1006022811895. Invest New Drugs. 1998. PMID: 9740539

6

Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.

Jean-Decoster C, Brichese L, Barret JM, Tollon Y, Kruczynski A, Hill BT, Wright M. Jean-Decoster C, et al. Among authors: kruczynski a. Anticancer Drugs. 1999 Jul;10(6):537-43. Anticancer Drugs. 1999. PMID: 10885901

7

Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.

van Hille B, Etiévant C, Barret JM, Kruczynski A, Hill BT. van Hille B, et al. Among authors: kruczynski a. Anticancer Drugs. 2000 Nov;11(10):829-41. doi: 10.1097/00001813-200011000-00007. Anticancer Drugs. 2000. PMID: 11142691

8

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT. Kruczynski A, et al. Br J Cancer. 2002 Jan 7;86(1):143-50. doi: 10.1038/sj.bjc.6600025. Br J Cancer. 2002. PMID: 11857026 Free PMC article.

9

Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.

Etiévant C, Kruczynski A, Barret JM, Perrin D, Hill BT. Etiévant C, et al. Among authors: kruczynski a. Biochem Pharmacol. 2003 Mar 1;65(5):755-63. doi: 10.1016/s0006-2952(02)01564-2. Biochem Pharmacol. 2003. PMID: 12628489

10

Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.

Kruczynski A, Barret JM, Van Hille B, Chansard N, Astruc J, Menon Y, Duchier C, Créancier L, Hill BT. Kruczynski A, et al. Clin Cancer Res. 2004 May 1;10(9):3156-68. doi: 10.1158/1078-0432.ccr-1305-2. Clin Cancer Res. 2004. PMID: 15131057

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page